Skip to content
thestock.space

On 6 Nov 2026, Prevest Denpro was priced at ₹397.85, or 22.0× trailing earnings, against an industry P/E of 28.6×, and the shares are 23% below their 52-week high. Sales and net profit grew 12% and 9.3% a year over 3 years; its ROCE of 22% is the second-highest among the 7 largest Medical Instruments & Supplies peers. Its dividend yield is 0.3%. It is listed on an SME platform with a market cap of ₹478 Cr, ranked 6th of 11 Medical Instruments & Supplies companies by market cap; the shares fell 21% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Jun 2026.How we calculate this

past year
Open
₹413.80
Day high
₹413.80
Day low
₹380.20
Prev. close
₹413.80
Volume
28.8K

Health check

3 good · 1 fair · 2 to check
  • ReturnsBehind

    −21.2% over a year, better than 2 of 7 peers.

  • Price tagCheaper

    P/E 22.0 vs industry 28.6.

  • GrowthSlow

    Sales +12.4%, profit +9.3% a year over 3 years.

  • ProfitabilityStrong

    ROCE 21.9% vs peer median 11.5%.

  • Balance sheetFair

    Piotroski 4 of 9.

  • Red flagsNone found

    No warning signs in the headline numbers.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Medical Instruments & Supplies

10 listed peers. Screen the industry

Small cap

₹478 Cr, #6 of 11 in its industry by size.

Defensive

Beta 0.56 vs the NIFTY 50: moves less than the market.

Key metrics

Last 12 months to Jun 2026: sales ₹75 Cr · profit ₹22 Cr
Market cap
₹478 Cr
Small cap
P/E
22.0
Industry 28.6
Price to book
3.83
Peers 5.26
Dividend yield
0.25%
ROE
17.8%
Peers 10.5%
ROCE
21.9%
Peers 11.5%
Debt to equity
n/a
Debt ₹0.00 Cr
EPS (TTM)
₹18.10
OPM (TTM)
34.8%
Net margin 28.9%
Sales growth
+20.9%
Latest quarter vs a year ago
Profit growth
+28.0%
Latest quarter vs a year ago
Price to sales
6.36
EV/EBITDA 15.1

Strengths and risks

Strengths

  • Return on capital employed of 21.9%.
  • Quarterly profit up 28.0% on a year ago.
  • Quarterly sales up 20.9% on a year ago.
  • Net margin of 28.9%.
  • Positive operating cash flow in each of the last 4 years.

No obvious red flags in the headline numbers.

Derived automatically from reported figures. Not a recommendation.

About Prevest Denpro

Prevest Denpro Limited, together with its subsidiaries, engages in the manufacturing and marketing of dental materials and allied products. The company offers clinical products, including adhesives, bonding agents, and etchants; auxiliaries; cement and liners; composites; endodontics; finishing and polishing; impression; orthodontics; retraction materials; temporaries; and tooth whitening products. It also provides laboratory products, such as acrylics,…

Headquarters
Jammu
Employees
139
Sector
Healthcare
ISIN
INE0GAO01018
Website
prevestdenpro.com

Price range

52 weeks

₹318.15₹514.00

Today

₹380.20₹413.80
Avg volume (3M)
16.1K
1-year return
minus 21.2%
From 52-week high
minus 22.6%

Peers · Medical Instruments & Supplies

Compare with peersScreen the whole industry
Company
LENSKARTLenskart Solutions724.75plus 0.89%1,25,562160.713.487.2%6.7%20.8%––0.00%plus 79.8%
AGARWALEYEDr. Agarwal's Health Care516.35plus 0.91%16,37394.17.669.7%6.8%15.0%26.9%12.3%0.00%minus 0.7%
POLYMEDPoly Medicure1,612.30plus 0.63%16,34351.45.2613.3%11.0%15.2%18.8%21.6%0.22%minus 18.1%
TARSONSTarsons Products316.95minus 0.46%1,686151.72.644.8%2.3%−0.9%14.3%−43.8%0.00%plus 10.9%
LAXMIDENTLLaxmi Dental196.42minus 0.05%1,08134.84.4411.5%12.8%16.4%19.5%–0.00%minus 37.9%
PREVESTPrevest Denpro397.85minus 3.85%47822.03.8321.9%17.8%34.8%12.4%9.3%0.25%minus 21.2%
QMSMEDIQMS Medical Allied Services168.66minus 0.69%32628.65.6818.4%10.5%12.0%18.4%16.7%0.30%plus 75.0%
SHREEPACShree Pacetronix170.00plus 0.32%6419.53.4125.0%19.7%24.8%2.2%−1.2%0.00%minus 38.5%
Median of 7 peers–0.32%1,68651.45.2611.5%10.5%15.2%18.6%12.3%0.00%−0.7%

Quarterly results

Consolidated, ₹ crore
SalesSelect a row below to chart it
₹ CrJun 25Sep 25Dec 25Mar 26Jun 26
15.818.618.518.919.1
10.51212.71212.3
5.36.75.86.96.8
33.7%35.8%31.4%36.5%35.5%
1.21.21.21.41.3
0.50.50.50.50.5
67.46.47.87.6
26.4%24.8%26.7%25.5%25.4%
4.45.54.75.85.6
3.674.623.934.854.70

Profit & loss

Yearly, ₹ crore
Sales CAGR 3Y
+12.4%
Profit CAGR 3Y
+9.3%
EPS CAGR 3Y
+9.3%
ROE
17.8%
Net profitSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
49.955.962.170.9
–+12.1%+11.0%+14.2%
3035.939.745.9
19.820.122.425
39.7%35.9%36.1%35.2%
1.82.73.84.6
0.71.31.92
0–−0.1−0
2121.424.227.6
25.0%24.7%25.1%25.8%
15.716.118.220.5
–+2.7%+12.5%+12.9%
13.0913.4515.1317.07

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore
Total assetsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
12121212
60.876.693.6113
−65.46.278.4
7.494.8113133
7.426.726.826.6
16.9–––
40.250.365.681.5
−57.117.820.125
7.494.8113133

Cash flow

Yearly, ₹ crore
Cash from operationsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
10.711.614.814.8
−12.4−1.7−1.3−1.6
−1.4−0.3−1.2−1.2
−3.19.612.312
−13.5−3.7−2−1.9
−2.97.912.812.9
–−0.3−1.2−1.2

Shareholding pattern

This company is listed only on BSE, so there’s no NSE category split. See Major shareholders below for the named holders.

Major shareholders

BSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you